Atlas, Sofinnova lead $45M investment in cancer startup
The founders of a small Cambridge startup helping to develop more effective drugs for cancer, autoimmune disorders and liver diseases like NASH are planning to double staff after closing a $45 million Series A venture capital investment.
The startup, HotSpot Therapeutics Inc., has developed a platform it calls SpotFinder, which it says can better identify protein targets or "hotspots," to enable drugmakers to develop more potent medications for a variety of diseases.
"What's exciting about HotSpot…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Allison DeAngelis Source Type: news
More News: Autoimmune Disease | Cancer | Cancer & Oncology | Health Management | Liver | Liver Disease | Urology & Nephrology | Venture Capital